Functional Genomic Screening to Identify Mechanisms of Platinum Resistance in Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer that is characterised by impressive initial response rates to platinum-based chemotherapy, followed by nearly universal relapse with platinum-resistant disease. Whilst some mechanisms of resistance have been identified, there has been a lack of comprehensive unbiased screening to survey the mechanisms of resistance in SCLC. To address this, I employed an unbiased whole-genome gain-of-function screening approach using CRISPR activation (CRISPRa) to identify genetic drivers of platinum resistance.